Furthermore, the Orient-31 trial explored a similar study approach in NSCLC patients after EGFR-TKIs resistance, validating that Sintilimab + the anti-angiogenic therapy biosimilar IBI305 + chemotherapy group had superior PFS and OS in comparison to the chemotherapy group [21]. Here, EGFR is linked to non-small cell lung carcinoma.